Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tenoxicam is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class, used primarily for its anti-inflammatory, analgesic, and antipyretic properties. It is indicated for the treatment of mild to moderate pain and the signs and symptoms associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, bursitis, periarthritis of shoulders or hips, gouty arthritis, sciatica, back pain, painful periods (dysmenorrhea), and postoperative pain[1][2][4][5][6][7]. The mechanism of action involves inhibition of cyclooxygenase enzymes (COX), specifically prostaglandin G/H synthase 1 and 2 (COX‑1 and COX‑2), leading to decreased synthesis of prostaglandins that mediate inflammation and sensitize pain receptors[1][6]. This results in reduced inflammation as well as peripheral analgesia. Antipyretic effects are thought to occur via central action on the hypothalamus[1]. Tenoxicam has a long duration of action allowing once-daily dosing[5], high protein binding (~99%)[4], rapid oral absorption with complete bioavailability[1], and an elimination half-life ranging from approximately 30–140 hours[4]. It was developed by Roche.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tenoxicam.